NRX Pharmaceuticals Inc
NASDAQ:NRXP
NRX Pharmaceuticals Inc
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. NRX-101 is a fixed-dose combination of D-cycloserine and lurasidone for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB). Its ZYESAMI (aviptadil) is an investigational drug for COVID-19-related respiratory failure. The firm has completed a Phase IIb/III clinical study in patients with acute respiratory failure in COVID-19.
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. NRX-101 is a fixed-dose combination of D-cycloserine and lurasidone for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB). Its ZYESAMI (aviptadil) is an investigational drug for COVID-19-related respiratory failure. The firm has completed a Phase IIb/III clinical study in patients with acute respiratory failure in COVID-19.
First Revenue: NRx Pharmaceuticals reported its first-ever revenue of about $240,000 in Q3, driven by the acquisition of medical clinics in Florida.
Clinic Expansion: The company moved from 2 to 3 clinics in Q3 and expects to grow to 6 or more clinics by year-end, projecting significant revenue growth ahead.
Cash Position: NRx ended Q3 with $7.1 million in cash, or $10.3 million including subsequent receipts, and anticipates this is enough to fund operations through at least Q2 2026.
R&D Progress: The company made major steps on drug development, advancing applications for KETAFREE (IV ketamine) and NRX-101, with large amounts of real-world data supporting their regulatory filings.
FDA Updates: The FDA identified no significant deficiencies in the KETAFREE filing, and the company anticipates a decision in Q2 2026; NRX-100 and NRX-101 filings are bolstered by breakthrough therapy and fast track designations.
DCS/TMS Results: Real-world and clinical data show high response and remission rates for severe depression using a combination of TMS and D-cycloserine (DCS), the active ingredient in NRX-101.
Market Opportunity: Management highlighted the potential for a generational shift in depression and PTSD treatment, with a new therapy model expected to expand coverage and payer support.
